Division of Infectious Diseases

Scott Letendre, M.D.

Scott Letendre, M.D.
Professor of Medicine

University of California, San Diego
HIV Neurobehavioral Research Center
Antiviral Research Center
150 West Washington Street
San Diego, California 92103

Telephone: (619) 543-8080
Email: sletendre@ucsd.edu

Dr. Letendre's Laboratory Website

Dr. Letendre's CV

HIV Neurobehavioral Research Center


Scott L. Letendre, M.D., is a Professor of Medicine in the Department of Medicine, Division of Infectious Diseases, at the University of California, San Diego (UCSD). He graduated from Georgetown University School of Medicine in 1986 and then completed his internship at Naval Hospital in Oakland, California. Following his residency in internal medicine at the Naval Medical Center in San Diego, he completed fellowships in infectious diseases at Duke University and in neurologic HIV research at UCSD. Dr. Letendre also has training in tropical medicine, cold weather medicine, and aerospace medicine.

Since joining the UCSD faculty in 2000, Dr. Letendre has conducted patient-oriented research of the correlates and consequences of chronic central nervous system infections, primarily HIV and HCV. He is also an active investigator in the UCSD unit of the AIDS Clinical Trials Group (ACTG, funded by the National Institutes of Health), and is currently a member of both the national ACTG Neurology Subcommittee and the ACTG Dementia Focus Group. Dr. Letendre has published extensively in peer-reviewed journals including AIDS, Neurology, Journal of Neuroimmunology, and The Journal of Infectious Diseases.

Research Interests

Dr. Letendre's research focuses on the impact on the brain of chronic infections and their treatment. The work is performed primarily at UCSD's HIV Neurobehavioral Research Center in Hillcrest and includes investigations of

In addition to U.S.-based projects, Dr. Letendre participates in similar studies in China, India, Brazil, and other venues.

Selected Publications

  1. Letendre SL, Lanier ER, McCutchan JA. Cerebrospinal Fluid Beta Chemokine Concentrations in Neurocognitively Impaired Individuals Infected with Human Immunodeficiency Virus Type 1. Journal of Infectious Diseases, 180: 310-9, 1999.
  2. Langford TD,Letendre SL (co-first author), Marcotte TD, Ellis RJ, McCutchan JA, Grant I, Mallory ME, Hansen LA, Archibald S, Jernigan T, Masliah E, and the HNRC Group. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS, 16(7):1019-1029, 2002.
  3. Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK, Grant I, Ellis RJ, and the HNRC Group. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol, 56(3):416-23, 2004.
  4. Letendre S, Marquie-Beck J, Singh KK, de Almeida S, Zimmerman J, Spector SA, Grant I, Ellis R; the HNRC Group. The monocyte chemotactic protein-1 -2578G allele is associated with elevated MCP-1 concentrations in cerebrospinal fluid. J Neuroimmunol, 157(1-2):193-196, 2004.
  5. Cherner M, Letendre S, Heaton RK, Durelle J, Marquie-Beck J, Gragg B, Grant I, and the HIV Neurobehavioral Research Group. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology, 64(8):1343-1347, 2005.
  6. Capparelli E, Holland D, Okamoto C, Gragg B, Durelle J, Marquie-Beck J, van den Brande G, Ellis R, Letendre S, and the HNRC Group. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS, 19(9):949-952, 2005.